Brokerages Set Disc Medicine, Inc. (NASDAQ:IRON) PT at $105.30

Disc Medicine, Inc. (NASDAQ:IRON) has been given a consensus rating of “Moderate Buy” by the twelve research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $105.30.

A number of equities research analysts recently weighed in on IRON shares. Cantor Fitzgerald lowered their target price on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th. Wedbush lowered their target price on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th. Truist Financial lowered their target price on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, BMO Capital Markets lowered their target price on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th.

Disc Medicine Price Performance

IRON stock opened at $66.82 on Tuesday. The firm has a 50 day moving average of $65.88 and a 200-day moving average of $74.36. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine has a 12 month low of $40.00 and a 12 month high of $99.50. The firm has a market capitalization of $2.55 billion, a P/E ratio of -10.09 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). As a group, sell-side analysts predict that Disc Medicine will post -6.78 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider William Jacob Savage sold 5,731 shares of the firm’s stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $66.38, for a total value of $380,423.78. Following the sale, the insider directly owned 79,480 shares of the company’s stock, valued at $5,275,882.40. This trade represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Jean M. Franchi sold 6,257 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the completion of the sale, the chief financial officer directly owned 64,333 shares in the company, valued at $4,454,416.92. This represents a 8.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 20,119 shares of company stock worth $1,351,699 over the last ninety days. 3.76% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Bank of America Corp DE raised its stake in shares of Disc Medicine by 22.6% during the first quarter. Bank of America Corp DE now owns 166,775 shares of the company’s stock worth $10,664,000 after acquiring an additional 30,789 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Disc Medicine by 47.8% during the first quarter. California State Teachers Retirement System now owns 34,382 shares of the company’s stock worth $2,198,000 after acquiring an additional 11,126 shares in the last quarter. SummitTX Capital L.P. purchased a new position in shares of Disc Medicine during the first quarter worth approximately $884,000. Octagon Capital Advisors LP purchased a new position in shares of Disc Medicine during the first quarter worth approximately $17,264,000. Finally, Entropy Technologies LP raised its stake in shares of Disc Medicine by 9.9% during the first quarter. Entropy Technologies LP now owns 4,788 shares of the company’s stock worth $306,000 after acquiring an additional 431 shares in the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.